SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics that address cancers and autoimmune diseases ...
Dr. Knobelman joined the Company on June 3, 2024 and oversees the finance, accounting, business development, investor relations and corporate strategy functions. Istisociclib (KB-0742), a CDK9 ...
SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent ...
Dallas, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $9.2 million, or $.08 per share, in the second quarter of 2025 compared to net income of ...
Kronos Worldwide (KRO) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.62 per share a year ago. These figures ...
LOWELL, Mass.--(BUSINESS WIRE)--Kronos: Employee shifts worked declined 8.8% compared to the week of May 18-24, 2020. However, the decline was predicted and closely mirrored the decline in shifts ...
SAN MATEO, Calif., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc., dedicated to targeting oncogenic transcription factors and their associated transcriptional regulatory networks, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback